Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports

Basit Öğe Kaydı
dc.contributor.authorTota, Maciej
dc.contributor.authorBaron, Vanessa
dc.contributor.authorMusial, Katie
dc.contributor.authorDerrough, Bouchra
dc.contributor.authorKonieczny, Andrzej
dc.contributor.authorKrajewska, Magdalena
dc.contributor.authorTurkmen, Kultigin
dc.date.accessioned2024-02-23T14:35:10Z
dc.date.available2024-02-23T14:35:10Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractPrimary (pIgAN), secondary IgA nephropathy (sIgAN), and IgA-associated nephropathy can be distinguished. While pIgAN has been thoroughly studied, information about the etiology of sIgAN remains scarce. As concerns sIgAN, several studies suggest that different etiologic factors play a role and ultimately lead to a pathophysiologic process similar to that of pIgAN. In this article, we review a vast number of cases in order to determine the novel putative underlying diseases of sIgAN. Moreover, updates on the common pathophysiology of primary disorders and sIgAN are presented. We identified liver, gastrointestinal, oncological, dermatological, autoimmune, and respiratory diseases, as well as infectious, iatrogenic, and environmental factors, as triggers of sIgAN. As novel biological therapies for listed underlying diseases emerge, we suggest implementing drug-induced sIgAN as a new significant category. Clinicians should acknowledge the possibility of sIgAN progression in patients treated with TNF-a inhibitors, IL-12/IL-23-inhibitors, immune checkpoint inhibitors, CTLA-4, oral anticoagulants, thioureylene derivatives, and anti-vascular endothelial growth factor drugs.en_US
dc.description.sponsorshipWroclaw Medical University [SUBZ.C160.23.046]en_US
dc.description.sponsorshipThis work was supported by Wroclaw Medical University subvention no SUBZ.C160.23.046.en_US
dc.identifier.doi10.3390/jcm12072726
dc.identifier.issn2077-0383
dc.identifier.issue7en_US
dc.identifier.pmid37048809en_US
dc.identifier.scopus2-s2.0-85152936892en_US
dc.identifier.urihttps://doi.org/10.3390/jcm12072726
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15914
dc.identifier.volume12en_US
dc.identifier.wosWOS:000969744300001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofJournal Of Clinical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIga-Associateden_US
dc.subjectGastrointestinalen_US
dc.subjectInfectionen_US
dc.subjectDermatologicalen_US
dc.subjectCanceren_US
dc.subjectLiveren_US
dc.subjectAutoimmuneen_US
dc.subjectDrug-Induceden_US
dc.subjectTreatmenten_US
dc.subjectPathophysiologyen_US
dc.titleSecondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reportsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu